Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 110 clinical trials
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

predictive factors leading to hematologic toxicity were a weight <77kg and an initial platelet count <175 G/L. However, it seems more complex as 50% of patients with an initial weight between 58 and

  • 0 views
  • 05 May, 2022
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

ULN absolute neutrophil count (ANC) ≥ 1,500 cells/µL platelet count ≥ 100,000/µL hemoglobin ≥ 9.0 g/dL Subjects who have at least a

metastatic pancreatic ductal adenocarcinoma
oxaliplatin
neutrophil count
folfox
metastasis
  • 1 views
  • 29 Jun, 2022
  • 1 location
Effect of Herbal Formulation on Karika Syrup on Thrombocytes Count

Effect of Herbal Formulation Karika Syrup on Thrombocyte Count.

platelet count
fatigue
Accepts healthy volunteers
  • 0 views
  • 28 Oct, 2022
  • 1 location
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

  • 6 views
  • 04 Mar, 2022
  • 1 location
Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (Circular)

To assess the efficacy and safety of an optimised dosing regimen of rhTPO's prophylactic treatment of cancer treatment-induced thrombocytopenia(CTIT) and to explore the cardioprotective effect of rhTPO in cancer patients with high risk of treatment-induced cardiac injury.

  • 0 views
  • 13 Jul, 2022
  • 1 location
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (Will-Plate)

Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.

clopidogrel
prasugrel
ticagrelor
coagulation factor
hemostatic
  • 0 views
  • 07 Oct, 2022
  • 1 location
Anti-BCMA CAR T-Cell Therapy for R/R ITP

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).

  • 0 views
  • 19 Apr, 2022
  • 1 location
Pro-thrombotic Status in Patients With SARS-Cov-2 Infection (ATTAC-Co)

The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. The observed patterns and changes will be related with inflammatory status, myocardial …

respiratory failure
pao2
mechanical ventilation
FIO2
SARS
  • 0 views
  • 04 Mar, 2022
  • 1 location
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension (APIS)

Intrahepatic non-cirrhotic portal hypertension (INCPH) is a rare disease mostly affecting adults in their forties, characterized by portal hypertension related to alterations of intrahepatic microcirculation in the absence of cirrhosis.The only therapeutic options currently available for patients with INCPH include prophylaxis for variceal bleeding using betablockers and/or endoscopic band ligation …

  • 3 views
  • 05 Apr, 2022
  • 1 location
Phase 2 Trial for Binimetinib for Patients With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not …

  • 6 views
  • 25 Oct, 2022
  • 1 location